Literature DB >> 28560665

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Charles A Kunos1, Evanthia Galanis2, Jeffrey Buchsbaum3, Qian Shi2, Lewis C Strauss4, C Norman Coleman3, Mansoor M Ahmed5,6.   

Abstract

Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

Entities:  

Keywords:  Cancer discovery; Clinical cancer research; Clinical trials; Experimental chemotherapy; Precision medicine; Radiotherapy

Mesh：

Substances：

Year:  2017        PMID： 28560665      PMCID： PMC5709276          DOI： 10.1007/s11060-017-2458-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  48 in total

Review 1.  Optimizing glioblastoma resection: intraoperative mapping and beyond.

Authors:  Joseph A Osorio; Manish K Aghi
Journal:  CNS Oncol       Date:  2014

2.  Rapid RBE-Weighted Proton Radiation Dosimetry Risk Assessment.

Authors:  Mohammad A Z Qutub; Susan B Klein; Jeffrey C Buchsbaum
Journal:  Technol Cancer Res Treat       Date:  2015-08-17

3.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

4.  Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Authors:  Evanthia Galanis; S Keith Anderson; Jackie M Lafky; Joon H Uhm; Caterina Giannini; Shaji K Kumar; Teresa K Kimlinger; Donald W Northfelt; Patrick J Flynn; Kurt A Jaeckle; Timothy J Kaufmann; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.

Authors:  Anand Veeravagu; Lewis C Hou; Andrew R Hsu; Weibo Cai; Joan M Greve; Xiaoyuan Chen; Victor Tse
Journal:  Neurol Res       Date:  2008-07-25       Impact factor: 2.448

7.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

8.  Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Authors:  Wolfgang Wick; Thierry Gorlia; Pierre Bady; Michael Platten; Martin J van den Bent; Martin J B Taphoorn; Jonathan Steuve; Alba A Brandes; Marie-France Hamou; Antje Wick; Markus Kosch; Michael Weller; Roger Stupp; Patrick Roth; Vassilis Golfinopoulos; Jean-Sebastien Frenel; Mario Campone; Damien Ricard; Christine Marosi; Salvador Villa; Astrid Weyerbrock; Kirsten Hopkins; Krisztian Homicsko; Benoit Lhermitte; Gianfranco Pesce; Monika E Hegi
Journal:  Clin Cancer Res       Date:  2016-05-03       Impact factor: 12.531

9.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

10.  Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters.

Authors:  Vikas Chandra; Tapojyoti Das; Puneet Gulati; Nidhan K Biswas; Sarang Rote; Uttara Chatterjee; Samarendra N Ghosh; Sumit Deb; Suniti K Saha; Anup K Chowdhury; Subhashish Ghosh; Charles M Rudin; Ankur Mukherjee; Analabha Basu; Surajit Dhara
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.